Cited 25 times in
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2018-09-28T08:52:32Z | - |
dc.date.available | 2018-09-28T08:52:32Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/163179 | - |
dc.description.abstract | BACKGROUND: We aimed to find the clinical value of metastatic tumor burden evaluated with F18-FDG PET/CT in gastric cancer patients, considering the human epidermal growth factor receptor 2 (HER2) status. METHODS: We retrospectively reviewed 124 patients with locally advanced or metastatic gastric cancer at Yonsei Cancer Center between January 2006 and December 2014 who had undergone baseline FDG PET/CT before first-line chemotherapy. We measured the maximum standardized uptake value from the primary tumor (SUVmax) and whole-body (WB) PET/CT parameters, including WB SUVmax, WB SUVmean, WB metabolic tumor volume (WB MTV), and WB total lesion glycolysis (WB TLG), in all metabolically active metastatic lesions (SUV threshold ≥2.5 or 40% isocontour for ≤2.5), and we determined their association with patient survival outcomes. RESULTS: SUVmax was higher in HER2-positive gastric cancers (median 12.1, range 3.4-34.6) compared to HER-2 negative (7.4, 1.6-39.1, P < 0.001). Among all patients, WB TLG > 600, which is indicative of a high metastatic tumor burden, showed worse progression-free survival (PFS) [hazard ratio (HR), 2.003; 95% CI, 1.300-3.086; P = 0.002] and overall survival (OS) (HR, 3.001; 95% CI, 1.950-4.618; P < 0.001) than did WB TLG ≤ 600. Among HER2-positive gastric cancer patients treated with trastuzumab, higher metabolic tumor burden predicted worse OS, but not PFS. CONCLUSIONS: HER2-positive gastric cancers had higher SUVmax compared to HER2-negative gastric cancers. In both HER2-negative patients and -positive patients receiving trastuzumab, FDG PET/CT volume-based parameters may have a role in further stratifying the prognosis of stage IV gastric cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group on behalf of Cancer Research UK | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Ian Chau | - |
dc.contributor.googleauthor | Joon Oh Park | - |
dc.contributor.googleauthor | Baek-Yeol Ryoo | - |
dc.contributor.googleauthor | Chia-Jui Yen | - |
dc.contributor.googleauthor | Ronnie Poon | - |
dc.contributor.googleauthor | Davide Pastorelli | - |
dc.contributor.googleauthor | Jean-Frédéric Blanc | - |
dc.contributor.googleauthor | Masatoshi Kudo | - |
dc.contributor.googleauthor | Tulio Pfiffer | - |
dc.contributor.googleauthor | Etsuro Hatano | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Katerina Kopeckova | - |
dc.contributor.googleauthor | Jean-Marc Phelip | - |
dc.contributor.googleauthor | Giovanni Brandi | - |
dc.contributor.googleauthor | Shinichi Ohkawa | - |
dc.contributor.googleauthor | Chung-Pin Li | - |
dc.contributor.googleauthor | Takuji Okusaka | - |
dc.contributor.googleauthor | Yanzhi Hsu | - |
dc.contributor.googleauthor | Paolo B. Abada | - |
dc.contributor.googleauthor | Andrew X. Zhu | - |
dc.identifier.doi | 10.1038/s41416-018-0103-0 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00406 | - |
dc.identifier.eissn | 1532-1827 | - |
dc.identifier.pmid | 29808014 | - |
dc.identifier.url | http://www.nature.com/articles/s41416-018-0103-0 | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 119 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 19 | - |
dc.citation.endPage | 26 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, Vol.119(1) : 19-26, 2018 | - |
dc.identifier.rimsid | 58447 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.